HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating for TransCode Therapeutics (NASDAQ:RNAZ) and maintained a price target of $3.
September 06, 2024 | 9:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for TransCode Therapeutics, maintaining a $3 price target. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. indicates a positive outlook for TransCode Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100